Contact
searchSearch
HMP Global
Login

Bipolar Disorders Topic Center

A baby resting on a mom's shoulder
News
Interpersonal Therapy Shows Promise for Perinatal Bipolar Disorder Management
05/07/2026
Maria Mantas
A pilot study found that an adapted version of Interpersonal and Social Rhythm Therapy (IPSRT) demonstrated both feasibility and high patient satisfaction across perinatal-specific challenges in pregnant women with bipolar disorder.
A pilot study found that an adapted version of Interpersonal and Social Rhythm Therapy (IPSRT) demonstrated both feasibility and high patient satisfaction across perinatal-specific challenges in pregnant women with bipolar disorder.
A pilot study found that an...
05/07/2026
Psych Congress Network
a printed test, pencil, and clock on a desk
Quiz
Mortality Risk in Bipolar II Disorder
04/30/2026
Maria Mantas
What was the association between all-cause mortality risk and bipolar II disorder? Test your knowledge with this quiz!
What was the association between all-cause mortality risk and bipolar II disorder? Test your knowledge with this quiz!
What was the association between...
04/30/2026
Psych Congress Network
A profile of a person split in half, one half teal and the other purple, with a swirl line over the head
News
Higher Risk of Premature Death Found in Bipolar II Disorder
04/07/2026
Brionna Mendoza
Bipolar II disorder (BD-II) is associated with significantly increased mortality, according to a large population-based cohort study published in JAMA Network Open.
Bipolar II disorder (BD-II) is associated with significantly increased mortality, according to a large population-based cohort study published in JAMA Network Open.
Bipolar II disorder (BD-II) is...
04/07/2026
Psych Congress Network
Food and Drug Administration building
News
FDA Approves Milsaperidone for Bipolar I and Schizophrenia in Adults
02/24/2026
Maria Mantas
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved...
02/24/2026
Psych Congress Network
Two pill bottles tipped over with pills on a table
News
Adolescent SSRI Use Not Causally Linked to Bipolar Disorder Risk, UK Registry Study Finds
01/06/2026
Sarah Fleming
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ...
01/06/2026
Psych Congress Network
artificial intelligence
News
AI-Based Prediction Tool Flags Psychotic and Bipolar Disorder Risk
01/05/2026
Maria Mantas
A large UK study reports that an artificial intelligence (AI)–enabled clinical prediction model may accurately identify individuals at risk of developing psychotic disorders or bipolar disorders.
A large UK study reports that an artificial intelligence (AI)–enabled clinical prediction model may accurately identify individuals at risk of developing psychotic disorders or bipolar disorders.
A large UK study reports that an...
01/05/2026
Psych Congress Network
Postpartum mother holding child
News
Postpartum Psychosis Should Be a Distinct Diagnosis, Experts Recommend
11/19/2025
Maria Mantas
An expert consensus panel is calling for postpartum psychosis (PP) to be recognized as a distinct diagnostic category in the DSM-5 and ICD-11.
An expert consensus panel is calling for postpartum psychosis (PP) to be recognized as a distinct diagnostic category in the DSM-5 and ICD-11.
An expert consensus panel is...
11/19/2025
Psych Congress Network
Covid-19
News
COVID-19 Post-Acute Sequelae More Likely in Patients With Serious Mental Illness
11/03/2025
Jolynn Tumolo
Patients with schizophrenia, bipolar disorder, or recurrent major depressive disorder have a higher risk of developing postacute sequelae of SARS-CoV-2 (PASC) than patients without serious mental illness.
Patients with schizophrenia, bipolar disorder, or recurrent major depressive disorder have a higher risk of developing postacute sequelae of SARS-CoV-2 (PASC) than patients without serious mental illness.
Patients with schizophrenia,...
11/03/2025
Psych Congress Network
US FDA sign
News
FDA OKs Once Monthly Subcutaneous Risperidone for Bipolar I Disorder
10/20/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug...
10/20/2025
Psych Congress Network
stethoscope, pills, and a brain
News
Stimulant Treatment for ADHD Associated With Psychosis and BD
09/25/2025
Maria Mantas
Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.
Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.
Stimulant use for the treatment...
09/25/2025
Psych Congress Network
DNA puzzle
News
Recent Cohort Study Assesses Genetic Relationships Between Psychotic Disorders
07/23/2025
Maria Mantas
From a genetic perspective, delusional disorder, acute psychoses, psychosis otherwise not specified, and schizoaffective disorder do not appear to be subtypes of schizophrenia, bipolar disorder, or major depression.
From a genetic perspective, delusional disorder, acute psychoses, psychosis otherwise not specified, and schizoaffective disorder do not appear to be subtypes of schizophrenia, bipolar disorder, or major depression.
From a genetic perspective,...
07/23/2025
Psych Congress Network

News

A profile of a person split in half, one half teal and the other purple, with a swirl line over the head
News
Higher Risk of Premature Death Found in Bipolar II Disorder
04/07/2026
Brionna Mendoza
Bipolar II disorder (BD-II) is associated with significantly increased mortality, according to a large population-based cohort study published in JAMA Network Open.
Bipolar II disorder (BD-II) is associated with significantly increased mortality, according to a large population-based cohort study published in JAMA Network Open.
Bipolar II disorder (BD-II) is...
04/07/2026
Psych Congress Network
Food and Drug Administration building
News
FDA Approves Milsaperidone for Bipolar I and Schizophrenia in Adults
02/24/2026
Maria Mantas
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved...
02/24/2026
Psych Congress Network
Two pill bottles tipped over with pills on a table
News
Adolescent SSRI Use Not Causally Linked to Bipolar Disorder Risk, UK Registry Study Finds
01/06/2026
Sarah Fleming
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ...
01/06/2026
Psych Congress Network
artificial intelligence
News
AI-Based Prediction Tool Flags Psychotic and Bipolar Disorder Risk
01/05/2026
Maria Mantas
A large UK study reports that an artificial intelligence (AI)–enabled clinical prediction model may accurately identify individuals at risk of developing psychotic disorders or bipolar disorders.
A large UK study reports that an artificial intelligence (AI)–enabled clinical prediction model may accurately identify individuals at risk of developing psychotic disorders or bipolar disorders.
A large UK study reports that an...
01/05/2026
Psych Congress Network
Postpartum mother holding child
News
Postpartum Psychosis Should Be a Distinct Diagnosis, Experts Recommend
11/19/2025
Maria Mantas
An expert consensus panel is calling for postpartum psychosis (PP) to be recognized as a distinct diagnostic category in the DSM-5 and ICD-11.
An expert consensus panel is calling for postpartum psychosis (PP) to be recognized as a distinct diagnostic category in the DSM-5 and ICD-11.
An expert consensus panel is...
11/19/2025
Psych Congress Network
Covid-19
News
COVID-19 Post-Acute Sequelae More Likely in Patients With Serious Mental Illness
11/03/2025
Jolynn Tumolo
Patients with schizophrenia, bipolar disorder, or recurrent major depressive disorder have a higher risk of developing postacute sequelae of SARS-CoV-2 (PASC) than patients without serious mental illness.
Patients with schizophrenia, bipolar disorder, or recurrent major depressive disorder have a higher risk of developing postacute sequelae of SARS-CoV-2 (PASC) than patients without serious mental illness.
Patients with schizophrenia,...
11/03/2025
Psych Congress Network
US FDA sign
News
FDA OKs Once Monthly Subcutaneous Risperidone for Bipolar I Disorder
10/20/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug...
10/20/2025
Psych Congress Network
stethoscope, pills, and a brain
News
Stimulant Treatment for ADHD Associated With Psychosis and BD
09/25/2025
Maria Mantas
Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.
Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.
Stimulant use for the treatment...
09/25/2025
Psych Congress Network
DNA puzzle
News
Recent Cohort Study Assesses Genetic Relationships Between Psychotic Disorders
07/23/2025
Maria Mantas
From a genetic perspective, delusional disorder, acute psychoses, psychosis otherwise not specified, and schizoaffective disorder do not appear to be subtypes of schizophrenia, bipolar disorder, or major depression.
From a genetic perspective, delusional disorder, acute psychoses, psychosis otherwise not specified, and schizoaffective disorder do not appear to be subtypes of schizophrenia, bipolar disorder, or major depression.
From a genetic perspective,...
07/23/2025
Psych Congress Network
Conference presenter
News
Olanzapine/Samidorphan Demonstrates Favorable Safety Profile in 4-Year Open-Label Study
11/01/2024
Brionna Mendoza
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination...
11/01/2024
Psych Congress Network
a woman scrolls on her phone while laying in bed
News
US Study Finds No Link Between AI Use and Depression
05/28/2026
Maria Mantas
A recent target trial emulation found no evidence of a causal relationship between frequent AI use and increased depressive symptoms among adults.
A recent target trial emulation found no evidence of a causal relationship between frequent AI use and increased depressive symptoms among adults.
A recent target trial emulation...
05/28/2026
Psych Congress Network
A clinician in the lab pulls a psilocybin mushroom from a bag using tweezers major depressive disorder mdd treatment
News
Single-Dose Psilocybin Rapidly Improves MDD Symptoms, RCT Finds
05/19/2026
Brionna Mendoza
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results.
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results.
A single dose of psilocybin was...
05/19/2026
Psych Congress Network
injection for schizophrenia treatment
News
Once-Monthly Aripiprazole Demonstrates Favorable Benefit–Risk Profile in Schizophrenia Treatment
05/14/2026
Maria Mantas
Once-monthly aripiprazole 400 mg (AOM 400) demonstrated a favorable risk-benefit profile as an acute and long-term maintenance treatment in patients with schizophrenia.
Once-monthly aripiprazole 400 mg (AOM 400) demonstrated a favorable risk-benefit profile as an acute and long-term maintenance treatment in patients with schizophrenia.
Once-monthly aripiprazole 400 mg...
05/14/2026
Psych Congress Network
A man with depression holds his head in his hands
News
Lumateperone Tops Efficacy in Adjunctive Treatment for MDD, Review Finds
05/12/2026
Brionna Mendoza
A new systematic review and network meta-analysis published in JAMA Psychiatry evaluated the comparative efficacy and acceptability of the 5 FDA-approved atypical antipsychotics used as adjunctive therapy for major depressive disorder (MDD).
A new systematic review and network meta-analysis published in JAMA Psychiatry evaluated the comparative efficacy and acceptability of the 5 FDA-approved atypical antipsychotics used as adjunctive therapy for major depressive disorder (MDD).
A new systematic review and...
05/12/2026
Psych Congress Network
A boy eating junk food while using a laptop computer
News
The Link Between Ultra-Processed Foods and ADHD
05/12/2026
Recent findings point to a possible link between ADHD and higher intake of ultra-processed foods.
Recent findings point to a possible link between ADHD and higher intake of ultra-processed foods.
Recent findings point to a...
05/12/2026
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy, with a human hand picking up the happy face
News
Semaglutide May Improve Motivation in MDD, Small Trial Finds
05/04/2026
Brionna Mendoza
A randomized clinical trial published in JAMA Psychiatry found that oral semaglutide may improve effort-based decision-making in adults with major depressive disorder (MDD).
A randomized clinical trial published in JAMA Psychiatry found that oral semaglutide may improve effort-based decision-making in adults with major depressive disorder (MDD).
A randomized clinical trial...
05/04/2026
Psych Congress Network
A patient receives psychedelic-assisted therapy
News
Presidential Executive Order Seeks to Expand Psychedelic Access for Tough-To-Treat Mental Illnesses
04/29/2026
Brionna Mendoza
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
President Donald J. Trump signed...
04/29/2026
Psych Congress Network
a female soldier stands in front of a row of American flags
News
TMS Improves Residential Therapy Outcomes in Combat-Related PTSD
04/22/2026
Maria Mantas
Active navigated transcranial magnetic stimulation (TMS) added to intensive residential treatment was associated with greater reduction of symptoms in patients with combat-related posttraumatic stress disorder (PTSD) than sham TMS.
Active navigated transcranial magnetic stimulation (TMS) added to intensive residential treatment was associated with greater reduction of symptoms in patients with combat-related posttraumatic stress disorder (PTSD) than sham TMS.
Active navigated transcranial...
04/22/2026
Psych Congress Network
A doctor sits at a table holding a pill bottle in one hand while filling out paperwork
News
Algorithm-Guided Treatment Improves Outcomes in Major Depressive Disorder
04/14/2026
Brionna Mendoza
A systematic review published in Frontiers in Psychiatry reports that algorithm-guided treatment (AGT) is generally associated with improved remission rates and more timely treatment modifications compared with treatment as usual (TAU).
A systematic review published in Frontiers in Psychiatry reports that algorithm-guided treatment (AGT) is generally associated with improved remission rates and more timely treatment modifications compared with treatment as usual (TAU).
A systematic review published in...
04/14/2026
Psych Congress Network
a person attempts to pick up a glass of water
News
Valbenazine Demonstrates Higher Persistence vs Deutetrabenazine in TD Patients
04/14/2026
Maria Mantas
Neurocrine Biosciences reported new real-world evidence demonstrating higher treatment persistence with valbenazine (Ingrezza) compared with deutetrabenazine (Austedo XR) among adults with tardive dyskinesia (TD).
Neurocrine Biosciences reported new real-world evidence demonstrating higher treatment persistence with valbenazine (Ingrezza) compared with deutetrabenazine (Austedo XR) among adults with tardive dyskinesia (TD).
Neurocrine Biosciences reported...
04/14/2026
Psych Congress Network

Quizzes

a printed test, pencil, and clock on a desk
Quiz
Mortality Risk in Bipolar II Disorder
04/30/2026
Maria Mantas
What was the association between all-cause mortality risk and bipolar II disorder? Test your knowledge with this quiz!
What was the association between all-cause mortality risk and bipolar II disorder? Test your knowledge with this quiz!
What was the association between...
04/30/2026
Psych Congress Network
Death risk increased by how much with a bipolar disorder diagnosis?
Quiz
Death risk increased by how much with a bipolar disorder diagnosis?
02/26/2024
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/26/2024
Psych Congress Network
polygenic risk scores
Quiz
Is there an association between hospitalization frequency and polygenic risk score?
10/06/2022
Take the quiz to test your clinical knowledge!
Take the quiz to test your clinical knowledge!
Take the quiz to test your...
10/06/2022
Psych Congress Network
COVID-19 risk.
Quiz
Antipsychotic Use and COVID-19 Risk in Patients with BD and SMI
06/15/2022
How does antipsychotic use affect COVID-19 risk? Take the quiz now to test your knowledge!
How does antipsychotic use affect COVID-19 risk? Take the quiz now to test your knowledge!
How does antipsychotic use...
06/15/2022
Psych Congress Network
Quiz
Challenges for Patients With Bipolar Disorder
01/11/2022
According to a recent survey, which of the following concerns did patients with bipolar-I disorder report?
According to a recent survey, which of the following concerns did patients with bipolar-I disorder report?
According to a recent survey,...
01/11/2022
Psych Congress Network
Girl in a classroom staring off into the distance
Quiz
Test Your Knowledge – Beyond the Stereotype: Rethinking Sex Differences in ADHD Presentation
05/12/2026
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation...
05/12/2026
Psych Congress Network
A boy eating junk food while using a laptop computer
Quiz
Test Your Knowledge: The Link Between Ultra-Processed Foods and ADHD
05/12/2026
How well do you understand the emerging evidence linking ultra-processed foods and ADHD? Assess your knowledge with this brief quiz.
How well do you understand the emerging evidence linking ultra-processed foods and ADHD? Assess your knowledge with this brief quiz.
How well do you understand the...
05/12/2026
Psych Congress Network
Nishi Bhopal, MD
Quiz
First Steps in Identifying Excessive Daytime Sleepiness
05/06/2026
Maria Mantas
What is the recommended first step to confirm whether a patient is experiencing excessive daytime sleepiness? Take this quick quiz to test your knowledge!
What is the recommended first step to confirm whether a patient is experiencing excessive daytime sleepiness? Take this quick quiz to test your knowledge!
What is the recommended first...
05/06/2026
Psych Congress Network
a printed test, pencil, and clock on a desk
Quiz
Mortality Risk in Bipolar II Disorder
04/30/2026
Maria Mantas
What was the association between all-cause mortality risk and bipolar II disorder? Test your knowledge with this quiz!
What was the association between all-cause mortality risk and bipolar II disorder? Test your knowledge with this quiz!
What was the association between...
04/30/2026
Psych Congress Network
an illustrated laptop screen displaying a quiz
Quiz
PGx Testing in MDD
04/27/2026
Maria Mantas
Can you recall how the use of pharmacogenomic testing impacted treatment outcomes in major depressive disorder (MDD)?
Can you recall how the use of pharmacogenomic testing impacted treatment outcomes in major depressive disorder (MDD)?
Can you recall how the use of...
04/27/2026
Psych Congress Network
a girl playing a game on a tablet while lying on her stomach
Quiz
Test Your Knowledge—Digital Therapeutics: A Different Treatment Modality for ADHD
04/23/2026
How familiar are you with DTx for the treatment of attention-deficit/hyperactivity disorder? Test your knowledge with this short, multiple-choice quiz.
How familiar are you with DTx for the treatment of attention-deficit/hyperactivity disorder? Test your knowledge with this short, multiple-choice quiz.
How familiar are you with DTx...
04/23/2026
Psych Congress Network
A boy's hand holding a pill that says ADHD
Quiz
Long-Term Effects of Viloxazine ER in Treatment of Pediatric ADHD
04/23/2026
Ready to apply the data? Test your knowledge of viloxazine ER for the long-term treatment of pediatric ADHD.
Ready to apply the data? Test your knowledge of viloxazine ER for the long-term treatment of pediatric ADHD.
Ready to apply the data? Test...
04/23/2026
Psych Congress Network
Brooke Kempf, PMHNP-BC, and Jonathan Meyer, MD
Quiz
Why should anticholinergics be avoided in TD?
04/17/2026
Maria Mantas
Do you remember why anticholinergic agents aren't appropriate treatment options for tardive dyskinesia? Test your knowledge with this quiz!
Do you remember why anticholinergic agents aren't appropriate treatment options for tardive dyskinesia? Test your knowledge with this quiz!
Do you remember why...
04/17/2026
Psych Congress Network
Brooke Kempf, PMHNP-BC, and Jonathan Meyer, MD
Quiz
Why should anticholinergics be avoided in TD?
04/17/2026
Maria Mantas
Do you remember why anticholinergic agents aren't appropriate treatment options for tardive dyskinesia? Test your knowledge with this quiz!
Do you remember why anticholinergic agents aren't appropriate treatment options for tardive dyskinesia? Test your knowledge with this quiz!
Do you remember why...
04/17/2026
Psych Congress Network
Edward Kaftarian, MD
Quiz
Legal Considerations in Cross-State Telepsychiatry
03/23/2026
Maria Mantas
Test your knowledge with this faculty insights quiz!
Test your knowledge with this faculty insights quiz!
Test your knowledge with this...
03/23/2026
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Insights
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use